Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

Recent Advances in Proteomic-based Approaches to Study Age-related Macular Degeneration: A Systematic Review

Version 1 : Received: 17 November 2022 / Approved: 18 November 2022 / Online: 18 November 2022 (06:57:26 CET)
Version 2 : Received: 18 November 2022 / Approved: 21 November 2022 / Online: 21 November 2022 (02:35:09 CET)

A peer-reviewed article of this Preprint also exists.

García-Quintanilla, L.; Rodríguez-Martínez, L.; Bandín-Vilar, E.; Gil-Martínez, M.; González-Barcia, M.; Mondelo-García, C.; Fernández-Ferreiro, A.; Mateos, J. Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review. Int. J. Mol. Sci. 2022, 23, 14759. García-Quintanilla, L.; Rodríguez-Martínez, L.; Bandín-Vilar, E.; Gil-Martínez, M.; González-Barcia, M.; Mondelo-García, C.; Fernández-Ferreiro, A.; Mateos, J. Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review. Int. J. Mol. Sci. 2022, 23, 14759.

Abstract

Age-related macular degeneration (AMD) is a common ocular disease characterized by the de-generation of the central area of the retina in elderly population. Progression and response to treatment is influenced by genetic and non-genetic factors. Proteomics is a powerful tool to study, at the molecular level, the mechanisms underlaying the progression of the diseases, to identify new therapeutical targets and to establish biomarkers to monitor progression and treatment ef-fectiveness. In this work we pursue to systematically review the use of proteomic-based ap-proaches for the study of the molecular mechanisms underlying the development of AMD, as well as the progression of the disease and the on-treatment patient monitoring. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines were followed. Proteomic approaches have identified key players on the onset of the disease, such as proteins involved in lipid metabolism and oxidative stress, but also in the progression to advanced stages, including factors related to extracellular matrix integrity and angiogenesis. Although an-ti-vascular endothelial growth factor (anti-VEGF)-based therapy has been crucial in the treatment of neovascular AMD it is necessary to get deeper into the underlying disease mechanisms to move forward to next-generation therapies of the later-stage forms of this multifactorial disease.

Keywords

Proteomics, Age-related macular degeneration, inflammation, biomarker, oxidative stress.

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (1)

Comment 1
Received: 21 November 2022
Commenter: Jesús Mateos
Commenter's Conflict of Interests: Author
Comment: Clean revised version.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.